Intec Pharma (NASDAQ:NTEC) is moving closer to data from its clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP). The AP is specifically designed to improve gastroretention as a controlled release solution for difficult-to-formulate drugs. The lead programme is a Phase III study of AP-CDLD (carbidopa and levodopa) in Parkinson’s, which is expected to be completely enrolled in Q417. It is also in a Phase I clinical study (targeting Q317 completion) of AP-CDB/THC (cannabidiol and tetrahydrocannabinol) for the treatment of pain and is seeking a development partner for is sleep aid, AP-ZP (zaleplon).
AP-CDLD to smooth Parkinson’s peaks and valleys
A persistent problem affecting Parkinson’s patients is that the primary drug used to treat the disease, levodopa has an exceptionally poor pharmacokinetic profile, leading to peaks in drug concentration when patients are troubled by dyskinesia and valleys when disease symptoms are not controlled. AP-CDLD directly addresses these shortcomings through improved gastroretention, providing a smooth profile and more consistent drug delivery.
To read the entire report Please click on the pdf File Below: